

# ICT<sup>®</sup> | INFECTION CONTROL T O D A Y<sup>®</sup>

October 2019 • Vol. 23 No. 8 • \$12.00 US

## Disposables

# Preparing for a Pandemic



### Vascular Access

Transition to Disposable  
Duodenoscope Endcaps

### Hand Hygiene

BUG OF THE MONTH  
Ready or Not, Here I Come

### Sterilization


Fighting Antibiotic Resistant Bacteria

### Vascular Access

Protocols to Improve UGPIV Safety

### Environmental Services

Product Locator



## COVER STORY

### Disposables


## 10 Preparing for a Pandemic

By Rachael Zimlich, RN, BSN

# contents

October 2019 | VOL. 23 | NO. 7

## COLUMNS & DEPARTMENTS



### Hand Hygiene

## 6 Bug of the Month

Ready or Not, Here I Come

By Daniel R. Verdon

### Environmental Services

## 22 Product Locator

## FEATURES

### Vascular Access

## 8 FDA: Healthcare Facilities Should Transition to Disposable Duodenoscopes

By Christine Blank

### Disinfection

## 14 Is Routine TB Testing Still Necessary for Healthcare Workers?

By Rachael Zimlich, RN, BSN

### Sterilization

## 17 DISARM Act Proposes New Strategies to Fight Antimicrobial Resistance

By Joan Vos Macdonald

### Vascular Access

## 20 Better Barriers and Standardized Protocols: Improving UGPIV Safety

By Nancy Moureau, RN, PhD, CRNI, CPUI, VA-BC

**ICT** INFECTION CONTROL TODAY

[www.infectioncontroltoday.com](http://www.infectioncontroltoday.com)

ICT (INFECTION CONTROL TODAY) (ISSN 1522-063X) is published monthly except combined issues for Jan/Feb and July/Aug (10 issue/Yr) by MultiMedia Healthcare LLC 325 W 1st St Duluth MN 55802. POSTMASTER: Please send address changes to: ICT, PO Box 6000, MN 55806-6000. Volume 23, Number 6. ICT subscription rates: 10 months print domestic \$52 and Canada USD \$115. All subscriptions are non-refundable. Prices subject to change. Free digital subscriptions available at [infectioncontroltoday.com](http://infectioncontroltoday.com) for US, Canada and other foreign subscribers. Copyright © 2018 2019 MultiMedia Healthcare LLC. All rights reserved. The publisher reserves the right to accept or reject any advertising or editorial material. Advertisers, and/or their agents, assume the responsibility for all content of published advertisements and assume responsibility for any claims against the publisher based on the advertisement. Editorial contributors assume responsibility for their published works and assume responsibility for any claims against the publisher based on the published work. No part of this publication may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. All items submitted to ICT become the sole property of MultiMedia Healthcare LLC. Editorial content may not necessarily reflect the views of the publisher.

COVER IMAGE: JIOMATHAI@STOCK.ADOBE.COM; USTAS@STOCK.ADOBE.COM

# Authoritative. Informative.

**THE MANDATE TO MAINTAIN AND FOLLOW MANUFACTURERS' MAINTENANCE DOCUMENTS AND SERVICE MANUALS**

THE ONESOURCE SAFETY AND COMPLIANCE SOLUTION

**onesource**  
SOLUTIONS LLC

ONESOURCEDOCS.COM | 1-800-701-3560  
Celebrating 10 years of changing the face of patient safety

**Evolving Technologies for Decontaminating Healthcare Environments**

ROBERT A. GARCIA, BS, MT(ASCP), CIC, FAPIC

CAS

**CleanSpace<sup>®</sup>**  
HEALTHCARE

EVERY BREATH COUNTS

**HEALTHCARE WORKER PROTECTION  
THE KEY TO SURVIVING THE NEXT  
RESPIRATORY OUTBREAK**

**SYNOPSIS**

Serious geopolitical and social forces are converging to create the conditions, on a scale unique in history, for a major respiratory pandemic.

Few hospitals - let alone the broader responder community - are ready for the acute scale up of trained personnel and equipment required to manage and contain a respiratory pandemic. In such a global crisis the initial phase will rely on the health and commitment of healthcare teams.

Prioritising protection of healthcare workers from primary to regional hospitals can ensure a resilient frontline defence. Logically when dealing with respiratory outbreaks, the focus is on the respiratory equipment.

© 2020 CleanSpace Healthcare. All rights reserved. CAS, CAS-1000, CAS-2000, CAS-3000, CAS-4000, CAS-5000, CAS-6000, CAS-7000, CAS-8000, CAS-9000, CAS-10000, CAS-11000, CAS-12000, CAS-13000, CAS-14000, CAS-15000, CAS-16000, CAS-17000, CAS-18000, CAS-19000, CAS-20000, CAS-21000, CAS-22000, CAS-23000, CAS-24000, CAS-25000, CAS-26000, CAS-27000, CAS-28000, CAS-29000, CAS-30000, CAS-31000, CAS-32000, CAS-33000, CAS-34000, CAS-35000, CAS-36000, CAS-37000, CAS-38000, CAS-39000, CAS-40000, CAS-41000, CAS-42000, CAS-43000, CAS-44000, CAS-45000, CAS-46000, CAS-47000, CAS-48000, CAS-49000, CAS-50000, CAS-51000, CAS-52000, CAS-53000, CAS-54000, CAS-55000, CAS-56000, CAS-57000, CAS-58000, CAS-59000, CAS-60000, CAS-61000, CAS-62000, CAS-63000, CAS-64000, CAS-65000, CAS-66000, CAS-67000, CAS-68000, CAS-69000, CAS-70000, CAS-71000, CAS-72000, CAS-73000, CAS-74000, CAS-75000, CAS-76000, CAS-77000, CAS-78000, CAS-79000, CAS-80000, CAS-81000, CAS-82000, CAS-83000, CAS-84000, CAS-85000, CAS-86000, CAS-87000, CAS-88000, CAS-89000, CAS-90000, CAS-91000, CAS-92000, CAS-93000, CAS-94000, CAS-95000, CAS-96000, CAS-97000, CAS-98000, CAS-99000, CAS-100000.

Download and read these whitepapers  
[InfectionControlToday.com/media-assets](https://www.infectioncontroltoday.com/media-assets)

Vascular Access

# Better Barriers and Standardized Protocols: Improving UGPIV Safety

By Nancy Moureau, RN, PhD, CRNI, CPU, VA-BC



**Mitigating cross-contamination risks during UPGIV procedures is essential for protecting patients and reducing costs.**

Insertion of a peripheral intravenous (PIV) catheter is the most commonly performed invasive medical procedure in acute care. It is estimated that more than 70 percent of hospitalized patients require peripheral IV access for the administration of medications, fluids, blood products, and/or nutrition.

Unfortunately, nearly 60 percent of those patients are considered to have difficult intravenous access. These patients can make PIV insertions challenging for even the most skilled clinician. Difficult access is caused by a variety of factors including aging veins, repeated cannulations, irritating medications, as well as obesity, IV drug use, and chronic conditions like diabetes and cancer. The high number of patients with difficult access has increased the use of ultrasound guidance to achieve successful PIV placement. It is estimated that ultrasound-guided PIV (UGPIV) insertions are now performed 12 million times per year in North America.

With the greater reliance on ultrasound to guide PIV insertions, organizations have published guidelines to promote safety by clarifying infection control practices for the procedure and disinfection of the ultrasound transducer, also commonly known as a probe. While there is agreement that the presence of both the probe and gel at the sterile insertion site pose a risk of infection, there is wide variation among the recommendations regarding standardization of the procedure, aseptic versus sterile technique, appropriate levels of probe disinfection, and specific infection control practices that should be followed.

## Benefits & Risks of UGPIV

Initially adopted by vascular access teams and emergency

departments, ultrasound guidance can be used in many care settings to overcome the challenges with gaining successful PIV insertion in patients with difficult access. According to the American Institute of Ultrasound in Medicine (AIUM), ultrasound guidance for PIV access can be an invaluable technique for patients who are difficult or seemingly impossible to access. Ultrasound guidance has been shown to improve IV success rates, decrease the number of percutaneous punctures and decrease the time required to achieve IV access. This can improve patient outcomes and lower costs associated with PIV insertions.

Yet UGPIV is not without risks. Research shows both probes and gels are frequently contaminated with bacteria, posing a serious risk of transmission between the ultrasound equipment, patients' skin and the bloodstream.

In one study, environmental organisms were found in 65 percent of samples taken from ultrasound equipment, while nearly 8 percent of samples included microorganisms that commonly cause infection. Another study reported a probe contamination rate of 17.5% following baseline cleaning methods. This contamination includes the potential for transmission of life-threatening *Staphylococcus aureus* to the patient's skin from the ultrasound equipment. According to Ohara et al., 60 percent of samples that tested positive for *Staphylococcus aureus* were methicillin-resistant (MRSA).

No one can argue that mitigating cross contamination risks during UPGIV procedures is essential for protecting patients and reducing costs. Most guidelines recommend some type of barrier/cover or protection film for the ultrasound probe; many also recommend sterile gel. However, research shows that even sterile probe covers

can fail; clinicians may inadvertently puncture covers with the access needles, causing site contamination. These contamination concerns have led to a greater focus on the level of disinfection a probe should undergo between procedures, which is precisely where many of the various guidelines differ.

## Confusion Over Disinfection Procedures

Most published guidelines rely on the use of the Spaulding Classification system, a widely accepted standard designed to determine the level of disinfection required for reusable medical devices based on the potential risk of infection posed to patients.

The Spaulding system has three device classification categories: critical, semi-critical, and non-critical. Devices that may come into contact with sterile tissue of the bloodstream are classified as critical. Devices that come into contact with non-intact skin, mucous membranes, blood or other bodily fluids are classified as semi-critical. Devices that only contact intact skin are considered non-critical.

Based on this system, critical and semi-critical devices require high-level disinfection (HLD), which is defined as the complete destruction of all microorganisms on or in a device. Devices used in non-critical procedures require low-level disinfection (LLD), typically achieved through the use of a germicidal spray or wipe to eliminate some viruses and bacteria. Differing interpretations of these categories, as well as data on the efficacy of various barrier methods, has led to different safety recommendations.

For instance, both AIUM and the American College of Emergency Physicians (ACEP) require the use of sterile gel and a protective cover during PIV procedures. The organizations conclude that with these infection control methods, LLD is justified. Other groups have a different take, including the CDC's Healthcare Infection Control Practices Advisory Committee (HICPAC), the Association for Vascular Access (AVA) and the Association for Professionals in Infection Control and Epidemiology (APIC). These groups assert that even with the use of probe covers, UGPIV is classified as semi-critical and therefore, HLD should be required before and after any insertion.

These differences may contribute to a lack of standardization with procedures and disinfection policies. A recent survey of U.S. infection preventionists revealed a high degree of non-compliance with infection control guidelines for UGPIV. According to author Ruth Carrico, only 22 percent of practitioners indicated using a probe that had undergone

HLD before or after performing a UGPIV insertion, and only one percent indicated using a sterile probe cover.

Similarly, a poll of vascular access clinicians conducted by this author in March 2019 revealed a significant gap between awareness of the risks of infection transmission and existing UGPIV practices. While 86 percent of respondents said they understand the probe and gel are potential sources of contamination, less than one-third said inserters at their facility always use sterile probe covers or sterile gel to maintain proper aseptic technique. Nearly 60 percent said their facilities have not established a standardized set of steps and policies regarding UGPIV insertions.

## *A recent survey of infection preventionists revealed a high degree of non-compliance with infection control guidelines for UGPIV.*

While hospital policies establish the management of probe disinfection, guidelines can help drive change based on the evidence. Currently, more organizations appear to be supportive of the greater safety controls of the Spaulding system by requiring HLD for ultrasound probes involved in any invasive procedure, including UGPIV insertions. APIC and AVA are currently working on revised guidelines to address these issues, which could provide much needed clarity for vascular access clinicians and infection control professionals

### Better Barrier Protection

In addition to proper disinfection, some barrier methods have been shown to be effective in safeguarding procedures and preventing further insertion site contamination. Barriers like sterile probe covers and use of transparent film dressings may provide more assurance of asepsis within the procedure, providing an added level of protection from pathogens.

It's important to note, however, that film dressings that are applied to the probe, such as Tegaderm, are not recommended by ultrasound manufacturers or organizations such as AVA. These dressings have great variability in application and may leave a film residue on the probe, resulting in deterioration of the vital transmission surface.


As an alternative to traditional sterile probe covers, facilities might consider a combination sterile barrier and film dressing that prevents

probe contact with blood or non-intact skin and uses layers of plastic over the dressing to reduce the risk of needle penetration. A sterile barrier and securement dressing like the UltraDrape™ (Parker Laboratories), designed specifically for UGPIV procedures, currently meets this criteria by separating the probe and gel from the insertion site. With this sterile barrier dressing, ultrasound gel is applied to a removable film layer. This keeps the puncture area dry and free from gel, while still enabling visualization of the target vessel through the dressing with ultrasound.

Even with proper disinfection, applying gel to the skin may contaminate the puncture site and leave behind gel residue, making dressing adherence difficult. A barrier and securement dressing that prevents gel from reaching the IV site enables clinicians to better maintain sterility of the needle, catheter, and prepped skin of the insertion area. This type of dressing also eliminates concerns about gel being accidentally injected into the bloodstream. The top layer where the gel is applied is discarded after use and the dressing slides over the IV catheter, effectively eliminating the time-consuming post-procedure skin clean up.

### Looking Ahead

There is a clear need for the vascular access community to establish a standardized protocol for ultrasound-guided peripheral IV insertions and probe disinfection. Ideally, guidelines will address issues including the use of probe covers, sterile gel, and barriers as well as appropriate probe disinfection procedures. We should look to the results of future studies to guide decisions for disinfection and aseptic management of UGPIV and other ultrasound-guided procedures.

Ensuring safety for patients is the ultimate goal, while also responsibly considering the time and cost required for UGPIV procedures. A standardized protocol, proper training for all staff members and teams involved in ultrasound-guided procedures, and the adoption of technology that promotes a more aseptic insertion technique may improve patient safety while increasing efficiency and lowering costs associated with UGPIV. 

*Nancy Moureau, RN, PhD, CRNI, CPUI, VA-BC, is an internationally recognized expert and speaker in the field of peripherally inserted central catheters and vascular access practice. As the owner and CEO of PICC Excellence, Moureau creates online educational programs and works with companies to provide education to clinicians. She can be reached at [nancy@piccexcellence.com](mailto:nancy@piccexcellence.com).*